If You Invested in Scpharmaceutical (SCPH)

scPharmaceuticals Inc. (SCPH) was a pharmaceutical company whose common stock traded on The Nasdaq Global Select Market under the symbol SCPH. According to company disclosures and public filings, scPharmaceuticals focused on cardiorenal care and described itself as a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations. The company was headquartered in Burlington, Massachusetts and operated in the manufacturing sector, with an industry classification in medicinal and botanical manufacturing.

In multiple public communications, scPharmaceuticals stated that its mission was centered on advancing cardiorenal care through integrated treatments that address unmet patient needs. It characterized its goal as becoming an advocate for patient-centric cardiorenal care and emphasized specialized, multidisciplinary approaches. The company indicated that it was expanding its reach by offering integrated therapies and products intended to address diverse healthcare needs and potentially improve patients’ lives.

Historically, scPharmaceuticals’ business was closely associated with FUROSCIX, a furosemide injection for subcutaneous use. Public releases describe FUROSCIX as indicated for the treatment of edema (congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure or chronic kidney disease, including the nephrotic syndrome. The company reported commercial activity around FUROSCIX, including net product revenues, dose volumes, and prescriber adoption, and highlighted its launch into the chronic kidney disease indication following U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) expanding the label.

scPharmaceuticals also disclosed development work on an 80 mg/1 mL FUROSCIX autoinjector program, referred to as SCP-111, which was described as designed to reduce administration time compared with the existing regimen. The company reported receiving multiple Notices of Allowance from the United States Patent and Trademark Office for patent applications covering the SCP-111 furosemide formulation and noted that this formulation was the subject of a planned supplemental NDA. These developments were presented as strengthening the company’s intellectual property portfolio and supporting next-generation formulations.

From a corporate structure and capital markets perspective, scPharmaceuticals was a public company with common stock registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on Nasdaq. Over time, the company filed periodic financial reports and multiple current reports on Form 8-K describing business updates, financing arrangements, and strategic transactions. These filings documented product revenues from FUROSCIX, research and development expenditures, selling, general and administrative expenses, and other financial metrics, as well as credit facilities and revenue participation agreements.

Acquisition by MannKind Corporation and Delisting

A significant corporate event occurred in 2025. On August 24, 2025, scPharmaceuticals entered into an Agreement and Plan of Merger with MannKind Corporation and a MannKind subsidiary, as described in a Form 8-K and subsequent press releases. Under this agreement, MannKind, through a tender offer, sought to acquire all outstanding shares of scPharmaceuticals common stock for a cash payment per share plus a non-tradable contingent value right (CVR) per share, with the CVR tied to specified regulatory and net sales milestones.

According to a Form 8-K dated October 7, 2025, the tender offer expired one minute after 11:59 p.m. Eastern time on October 6, 2025. Shares representing approximately 73.47% of the issued and outstanding common stock were validly tendered and not withdrawn, with additional shares subject to guaranteed delivery. The filing states that all conditions to the offer were satisfied, the offer was completed, and MannKind caused its merger subsidiary to merge with and into scPharmaceuticals on October 7, 2025. At the effective time of the merger, scPharmaceuticals became a direct wholly owned subsidiary of MannKind, and each share of scPharmaceuticals common stock (other than specified excluded shares and appraisal shares) was converted into the right to receive the offer consideration.

The same Form 8-K reports that, in connection with the consummation of the merger, scPharmaceuticals notified The Nasdaq Global Select Market of the transaction and requested that Nasdaq file a Form 25 to remove the company’s common stock from listing and registration. Trading in SCPH shares was halted prior to the open of trading on October 7, 2025. A separate Form 25 filed by Nasdaq on October 7, 2025 confirms the notification of removal from listing and/or registration under Section 12(b) of the Exchange Act for scPharmaceuticals Inc. common stock on The Nasdaq Stock Market LLC.

As a result of these steps, SCPH ceased trading on Nasdaq and scPharmaceuticals transitioned from an independent public company to a wholly owned subsidiary of MannKind. The October 7, 2025 Form 8-K further notes that the company intended to file a Form 15 to terminate registration of its shares under the Exchange Act and suspend its reporting obligations.

Business Focus and Therapeutic Area

Across its public communications, scPharmaceuticals consistently described itself as focused on cardiorenal healthcare and patient-centric care models. The company’s disclosures emphasize:

• A mission to advance cardiorenal care through integrated treatments addressing unmet patient needs.
• An aspiration to act as an advocate for patient-centric cardiorenal care and to drive health improvements through specialized, multidisciplinary approaches.
• Expansion of its reach through therapies and products that address diverse healthcare needs, with the stated aim of potentially improving patients’ lives.

Earlier descriptions also characterize scPharmaceuticals as a clinical-stage pharmaceutical company focused on developing and commercializing products designed to enable subcutaneous administration of therapies previously limited to intravenous delivery, with the goal of transforming infused therapies, advancing patient care, and reducing healthcare costs. This aligns with the company’s work on subcutaneous furosemide administration for patients with chronic heart failure and chronic kidney disease.

Regulatory and Intellectual Property Highlights

Key regulatory and intellectual property elements documented in company communications include:

• FDA approval of FUROSCIX for treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome.
• FDA approval of an expanded FUROSCIX indication to include treatment of edema in patients with chronic kidney disease, followed by a formal launch into that indication.
• Development of the SCP-111 furosemide formulation and related autoinjector program, with multiple Notices of Allowance from the U.S. Patent and Trademark Office for patent applications covering this formulation.
• Plans and disclosures regarding supplemental NDA filings for SCP-111 and the FUROSCIX autoinjector.

These elements illustrate how scPharmaceuticals sought to build a franchise around subcutaneous furosemide administration, supported by regulatory approvals and patent protection.

Post-Acquisition Status and Investor Context

For investors researching SCPH as a stock, it is important to note that, based on the October 7, 2025 Form 8-K and the Form 25 filed the same day, scPharmaceuticals’ common stock was delisted from Nasdaq following its acquisition by MannKind and the completion of the merger. scPharmaceuticals continues as a corporate entity but as a wholly owned subsidiary of MannKind rather than as an independent public issuer. Historical financial statements, 8-Ks, and other SEC filings for scPharmaceuticals therefore provide context on its operations and capital structure prior to the acquisition, while more recent information about the FUROSCIX franchise and related assets may be reflected in MannKind’s disclosures.

Users reviewing SCPH on Stock Titan are typically accessing a historical record of scPharmaceuticals as a stand-alone public company, including its cardiorenal focus, FUROSCIX-related activities, and the sequence of events that culminated in its acquisition and delisting.